Baclofen

Intrathecal baclofen therapy for ms ; what is baclofen. Men prmru anagennho vlasovho stvolu pomoc optick mikroskopie ukzalo statisticky signifikantn zvsen po 6 mscch p 0.02 ; a po 9 mscch p 0.001 ; . Metodou skenovac elektronov mikroskopie nebyly nalezeny zdn morfologick zmny. Dv pacientky studii perusily kvli podrzdn kze v mst aplikace, kter bylo zpsobeno isopropanolem. Nebyly nalezeny zmny v biochemickch nebo hematologickch hodnotch a vyhodnocen dotaznk svdc pro to, ze aplikovan Eucapil nevykazuje systmov cinky. Eucapil je dky sv bezpecnosti a cinnosti lkavou alternativou v lcb AGA u zen. Acknowledgement The study was sponsored by Interpharma Praha, a.s., and supported from the research concept of the Czech Ministry of Education 6198959216 ; . REFERENCES 1. Hoffmann R, Happle R. Current understanding of androgenetic alopecia. Part II: clinical aspects and treatment. Eur j Dermatol 2000; 10: 410417. Hoffmann R, Happle R. Current understanding of androgenetic alopecia. Part I: Etiopathogenesis. Eur j Dermatol 2000; 10: 319326. Birch MP, Messenger AG. Genetic factors predispose to balding and non-balding in men. Eur j Dermatol 2001; 11: 309314. Wolff H, Kunte CH. Current management of androgenetic alopecia in men. Eur j Dermatol 1999; 9: 6069. Hoffmann R. Steroidogenic isoenzymes in human hair and their potential role in androgenetic alopecia. Dermatology 2003; 206: 8596. Kaufman KD. Androgens and alopecia. Molecular and Cellular Endocrinology 2002; 198: 8995. Tosti A, Camacho-Martinez F, Dawber R. Management of androgenetic alopecia. journal of the European Academy of Dermatology and venereology 1999; 12: 205214. Sawaya ME, Shapiro J. Androgenetic alopecia. New approved and unapproved treatments. Dermatologic Clinics 2000; 18: 4762. Ludwig E. Classification of the types of androgenetic alopecia common baldness ; occurring in the female sex. Brit j Dermatol 1977; 97: 247254. Treb MR. Molecular mechanism of androgenetic alopecia. Experimental Gerontology 2002; 37: 98190. Jaworsky C, Kligman AM, Murphy GF. Characterisation of inflammatory infiltrates in male pattern alopecia: implication for pathogenesis. Br j Dermatol 1992; 127: 239246. Whiting DA. Diagnostic and predictive value of horizontal sections of scalp biopsy specimens in male pattern androgenetic alopecia. Acad Dermatol 1993; 28: 755763. Braun-Falco O, Plewig G., Wolff HH. Dermatology and venereology, 2nd ed., Berlin, Springer verlag 2000: 11181134. 14. Schindler AE. Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception. Eur j Obstet Gynecol Repr Biol 2004; 112: 136141. Wiegratz I, Kuhl H. Managing cutaneous manifestations of hyperandrogenic disorders. The role of oral contraceptives. Treat Endocrinol 2002; 1 6 ; : 373386. 16. Schneider HPG. Androgens and antiandrogens. Ann Ny Acad Sci 2003; 997: 292306. Raudrand D, Rabe T. Progestogens with antiandrogenic properties. Drugs 2003; 63 5 ; : 463492. 18. Suchopr J. Kapitola 6, Lciva pouzvan k terapii nemoc endokrinnho systmu [Chapter 6, Drugs used for the therapy of endocrine system diseases]. In: simek R, ed. Remedia compendium, Prague: Lciva, 1999: 384. 19. Seligson L, Campion BK, Brown JW, et al. Development of fluridil, a topical suppressor of the androgen receptor in androgenetic alopecia. Drug Development Research 2003; 59: 292306. Sovk M, Seligson AL, Kucerova R, et al. Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience. Dermatol Surgery 2003; 28: 678685.

Methods Population: MS and SCI C5-T11, Frankel A-D ; SCI n 12 ; . Treatment Intrathecal baclofen pump implantation. Outcome Measures: Ashworth, spasm frequency score, FIM. 1.
8. Royal Australian and New Zealand College of Psychiatrists, Royal Australian College of General Practitioners, Royal Australasian College of Physicians. Clinical guidance on the use of antidepressant medications in children and adolescents. : racgp .au folder ?id 1180 [cited 2005 Aug 22].
Buy cheap baclofen online
Sedative-hypnotics estazolam temazepam triazolam AMBIEN RESTORIL 7.5 MG LUNESTA Skeletal Muscle Relaxants baclofen chlorzoxazone cyclobenzaprine dantrolene methocarbamol orphenadrine oral tizanidine SKELAXIN LIORESAL INJ ORPHENADRINE INJ Electrolytes Minerals folic acid kaon-cl klor-con levocarnitine oral phospha potass cit citric acid potassium chloride oral sodium chloride irrigating soln sodium citrate citric acid K-DUR K-PHOS MICRO-K NICOMIDE PHOSLO V-C FORTE.
Published by : qbmaurer : 5 0 baclofen baclofen, baclofen topic cloud, transverse myelitis internet club list baclofen pump and lioresal.
Drug Name SUTENT CAP 12.5MG Sunitinib Malate ; SUTENT CAP 25MG Sunitinib Malate ; SUTENT CAP 50MG Sunitinib Malate ; tamoxifen citrate tab 10 mg base equivalent ; tamoxifen citrate tab 20 mg base equivalent ; TARCEVA TAB 100MG Erlotinib ; TARCEVA TAB 150MG Erlotinib ; TARCEVA TAB 25MG Erlotinib ; TARGRETIN CAP 75MG Bexarotene ; TAXOTERE INJ 20 0.5ML Docetaxel ; TAXOTERE INJ 80MG 2ML Docetaxel ; TESLAC TAB 50MG Testolactone ; TRISENOX SOL 10MG 10M Arsenic Trioxide ; VESANOID CAP 10 MG Tretinoin Chemotherapy VIADUR KIT Leuprolide Acetate ; VIDAZA INJ 100MG Azacitidine ; XELODA TAB 150MG Capecitabine ; XELODA TAB 500MG Capecitabine ; ZOLADEX IMP 10.8MG Goserelin Acetate ; ZOLADEX IMP 3.6MG Goserelin Acetate ; ZOLINZA CAP 100MG Vorinostat ; 12000000 Autonomic Drugs ADVAIR DISKU MIS 100 50 Fluticasone-Salmeterol ; ADVAIR DISKU MIS 250 50 Fluticasone-Salmeterol ; ADVAIR DISKU MIS 500 50 Fluticasone-Salmeterol ; ADVAIR HFA AER 115 21 Fluticasone-Salmeterol ; ADVAIR HFA AER 230 21 Fluticasone-Salmeterol ; ADVAIR HFA AER 45 21 Fluticasone-Salmeterol ; AKINETON TAB 2MG Biperiden HCl ; albuterol inhal aerosol 90 mcg act albuterol sulfate inhal aero 108 mcg act 90mcg base equiv ; albuterol sulfate soln nebu 0.083% 2.5 mg 3ml ; albuterol sulfate soln nebu 0.5% mg ml ; albuterol sulfate soln nebu 1.25 mg 3ml base equiv ; albuterol sulfate syrup 2 mg 5ml albuterol sulfate tab 2 mg albuterol sulfate tab 4 mg ALUPENT INH AER 0.65 ACT Metaproterenol Sulfate ; ARICEPT TAB 10MG Donepezil Hydrochloride ; ARICEPT TAB 5MG Donepezil Hydrochloride ; ARICEPT ODT TAB 10MG Donepezil Hydrochloride ; ARICEPT ODT TAB 5MG Donepezil Hydrochloride ; atropine sulfate inj 0.05 mg ml atropine sulfate inj 0.1 mg ml atropine sulfate inj 0.4 mg ml atropine sulfate inj 0.8 mg ml atropine sulfate inj 1 mg ml ATROVENT HFA AER 17MCG Ipratropium Bromide HFA ; baclofen tab 10 mg. Transmitters possibly including substance P ; from nociceptive afferent nerve endings. The analgesic efficacy of baclofen in trigeminal neuralgia has been established. Baclofen can also be used empirically in treating myofascial pain syndromes and other types of lancinating or paroxysmal neuropathic pains in which muscle spasm is contributing to the pain. It can be started at a dose of 5 mg, po, tid, which can be gradually titrated up until favorable effects occur or side-effects supervene. Common side-effects include nausea, confusion, drowsiness, dizziness, and hypotension. Baclofen should not be abruptly withdrawn as this may produce seizures and hallucinations. Antihypertensive drugs I. Clonidine Catapres ; , an 2-adrenergic agonist and 1-adrenergic blocker, is a multipurpose adjuvant analgesic, which is beneficial in various neuropathic pain syndromes, including migraine, postoperative pain, painful diabetic neuropathy, postherpetic neuralgia, nocturnal leg pains, sympathetically maintained pain, and cancer pain. It is considered as a "beyond second-line" drug see Table 5.10-4 ; in the management of neuropathic pain in patients refractory to trials of NSAIDs, antidepressants, and other drugs. The mechanism of action of its analgesic effect is probably related to its effects on norepinephrine as well as its inhibition of firing of dorsal horn nociceptors. Clonidine can be administered through the oral route Catapres ; , transdermal route Catapres TTS ; , or intrathecal route Duraclon ; . Choice of either oral or transdermal route is based on patient preference. To avoid adverse effects especially hypotension ; , the oral dose is started at 0.1 mg day, po, then gradually increased until side-effects occur or a significant effect on blood pressure is noted usual analgesic dose is 0.10.4 mg day; maximum of 2.4 mg day ; . See Chapter 4.8, section IX.A.1 and Chapter 5.4, section III.D.1.d for details about its ADRs, contraindications and precautions, and dosing administration guidelines. When administered intrathecally epidurally ; , it has an effect on the descending noradrenergic pathways, which produces analgesia this effect is unfortunately not associated with oral administration ; . Intrathecal clonidine is approved for treatment of severe neuropathic pain in cancer patients that is not adequately relieved by opioid analgesics alone. The recommended starting dose of Duraclon for continuous epidural infusion is 30 g hour, which can be titrated either up to 40 hour ; or down depending on pain relief and occurrence of adverse events. There has also been a report of the analgesic efficacy of long-term use of continuous intrathecal clonidine at 5075 g hour ; in patients with chronic, intractable, noncancer pain using an implanted programmable pump. II. Prazosin Minipress ; is a selective 1-adrenergic blocker, which has anecdotally been reported to be effective for neuropathic pain, possibly from upregulation of 1-adrenergic receptors in injured nerves. Its ADRs include hypotension, syncope, dizziness, headache, drowsiness, lack of energy, weakness, palpitations, and nausea. It can be started at 1 mg, po, qhs, then gradually titrated up to 412 mg day maximum daily dose is 20 mg in divided doses ; . It is available in 1-, 2-, and 5-mg capsule forms. See also Chapter 4.8, section IX.A.3. III. Phenoxybenzamine Dibenzyline ; , an 1- and 2-adrenergic blocker primarily used in the management of hypertension in patients with pheochromocytoma, has been anecdotally reported to be effective in relieving pain by producing and maintaining "chemical sympathectomy" in selected cases of CRPS and possibly painful plexopathies. Because of unopposed -adrenergic activity, there is exaggerated hypotension and tachycardia. If these side-effects are intolerable, a -blocker e.g., propranolol ; may be used concomitantly and benazepril. Local pharmacy provides meds for initial fill then mail order local pharmacy provides meds for initial fill then mail order 4-6 weeks min.

Reverse t negative feedback until further notice, i will report on baclofen over on the mens health forum under the same heading as here and betahistine.

Buy cheap baclofen

Convulsions after withdrawal of baclofen are well reported in adults. The present study shows that the GABAB receptor agonist baclofen microinjected into the NTS increases arterial pressure in conscious rats. Other studies 14, 15 ; showed that GABA microinjections into the NTS increase blood pressure in anesthetized rats. These studies also reported that microinjections of the GABAA antagonist bicuculine produce hypotension in anesthetized rats 14, 15 ; . Bilateral microinjection of muscimol GABAA agonist ; 7 ; , or electrolytic and chemical lesions 1 ; or bilateral microinjections of baclofen into the NTS 9 ; , elicits tachycardia in anesthetized animals. Our study demonstrated that a GABAB-selective agonist also elicits a pressor response in conscious rats. Only animals that received microinjections of baclofen at the highest dose 1, 000 pmol 100 nl ; displayed tachycardia, whereas the other doses did not demonstrate consistent changes in HR. An exception was that, in the second protocol, 100 pmol 100 nl baclofen produced a significant tachycardia. This result could be due to the highest variance observed in HR basal level. We would expect that such an effect could result from baroreflex and betamethasone.

Tardive dyskinesia and tardive dementia from antidepressants many clinicians continue to believe that only the neuroleptics, and not the antidepressants, cause tardive dyskinesia, with its permanent, untreatable tics and spasms of the voluntary muscles!

37 s-3 39th page of 73 toc 1st previous next bottom just 39th security ownership of certain beneficial owners and management - the table below sets forth the beneficial ownership of the common stock as of september 30, 1997 i ; by each director, ii ; by each of the executive officers of the company , iii ; by all directors and executive officers of the company as a group, and iv ; by the persons known by the board of directors to be beneficial owners of more than five percent of the outstanding shares of common stock and bethanechol. Causes and pharmacological treatment of ADHD. The British emphasis is on social causes and the psychological treatment of a conduct disorder. How do you make a diagnosis of ADHD? Learning disabilities, hyperactivity, emotional instability, easy distractibility, short attention span, general coordination deficit and "acting before thinking" characterize ADHD See table 1: DSM-IV diagnostic criteria for ADHD ; Imagine the following scenario: Michael is a very active seven-yearold who starts first grade in public school. His teacher quickly notices that he is always figidty, restless, disrup. Baclofen - oral and intrathecal pump baclofen is a gaba agonist, and its primary site of action is the spinal cord, where it reduces the release of excitatory neurotransmitters and substance p by binding to the gaba-b receptor and urecholine. T's a treatment for alleviating spasticity in people with spinal cord injury. But the intrathecal baclofen pump has also caused a headache for facilities as they try to manage the increasing number of patients receiving this treatment. The pump, placed just below the skin in the abdomen, infuses a preset dosage of baclofen via catheter to the spinal canal, eliminating the need for oral baclofen. The increase in patients' being tested for and undergoing this procedure at The Institute for Rehabilitation and Research in Houston meant that the system for treating and tracking these patients was no longer sufficient. A new procedure had to be developed that would streamline the process while allowing better record-keeping, and would serve both patients and staff. Under the old system, patients were required to come to the hospital for several visits so that each discipline could perform evaluations. There was no common documentation, which hampered the already difficult task of justifying the implants to payers. In addition, no predetermined schedule for follow-up evaluations was in place during the trial injection. Each discipline performed its post-trial evaluations whenever the patient was available, making documentation, communication and timing problematical. It also allows the team members to decide immediately whether the trial has succeeded and permanent implantation can proceed, or whether a retrial is necessary. The physical and occupational therapists initiate this form during the pretrial evaluation. It is then placed in the patient's medical record to allow all disciplines access to the form on the day of the trial. Despite treating about 1000 patients with maois in my career, i have rarely seen even minor morbidity from hypertensive reactions, which are easily treatable and bicalutamide. Eight medical admissi use economic damages baclofen thereafter. Overall, tizanidine is well tolerated. The most frequent side-effects mentioned are drowsiness and a dry mouth. In general, a reduction in spasticity was not achieved at the expense of muscle strength. Tizanidine was better tolerated than diazepam, but there appeared to be little difference between it and baclofen in terms of frequency and severity of side-effects. However, in the only study where individual overall preferences were assessed, patients, investigators and physiotherapists preferred baclofen over tizanidine and casodex.
Many people find it tempting to oversimplify disease. Dr. Hulda Clark, for example, wrote the following in the beginning of her book, The Cure for All Diseases: "No matter how long and confusing is the list of symptoms a person has, from chronic fatigue to infertility to mental problems, I sure to find only two things wrong: they have in them pollutants and or parasites. I never find lack of exercise, vitamin deficiencies, hormone levels or anything else to be a primary causative factor. So the solution to good health is obvious: Problem Parasites Pollution Simplest Cure Electronic and herbal treatment Avoidance.
Andrade R, Malenka RC, Nicoll RA 1986 ; A G-protein couples serotonin and GABA, receptors to the same channels in hipposampus. Science 234: 1261-1265. Burke SP, Nadler JV 1988 ; Regulation of glutamate and aspartate release from slices of the hippocampal CA, area: effects of adenosine and baclofen. J Neurochem 5 1: 1541-l Dolphin AC, Forda SR, Scott RH 1986 ; Calcium-dependent currents in cultured rat dorsal root ganglion neurones are inhibited by an adenosine analogue. J Physiol Lond ; 373~47-61. Dunwiddie TV 1985 ; The physiological role of adenosine in the central nervous system. Int Rev Neurobiol27: 63-139. Fredholm BB, Dunwiddie TV 1988 ; How does adenosine inhibit transmitter release? Trends Pharm Sci 9: 130-l 34. Fredholm BB. Proctor W. Ploea IV. Dunwiddie TV 1989 ; In viva pertussis toxin treatment atte&ates some, but not all, adenosine A, effects in slices of the rat hippocampus. Eur J Pharmacol 172: 249262. Gerber V, Greene RW, Haas HL, Stevens DR 1989 ; Characterization of inhibition mediated by adenosine in the hippocampus of the rat in vitro. J Physiol Lond ; 417: 567-578. Hamill OP, Marty A, Neher E, Sakmann B, S&worth FJ 1981 ; Improved patch-clamp techniques for high resolution current recordings from cells and cell-free membrane patches. Pfluegers Arch 391: 85100. Harrison NL 1990 ; On the presynaptic action of baclofen at inhibitory synapses between cultured rat hippocampal neurons. J Physiol Lond ; 422~433446. Hollins C, Stone TW 1980 ; Adenosine inhibition of y-aminobutyric acid release from slices of rat cerebral cortex. Br J Pharmacol69: 107 and bisoprolol and baclofen.

330 employees of the Department of Corrections have prepared reports which were part of the departmental report. In light of the departmental report, the Claimant's testimony is not persuasive. The weight of the evidence established by the Department of Corrections employees is that the chain of events which ultimately led to the Claimant's injury began long after the Claimant had returned to the cellhouse. The officer who allowed the Claimant back into the cellhouse was attacked and seriously injured subsequent to the time he let the Claimant in. The Claimant's own testimony established that Officer Derickson who checked his "cell pass" did not appear to be upset or agitated at the time he was let back into the cellhouse. Since the attack on Officer Derickson obviously took place after the Claimant was let back into the cellhouse, a significant amount of time had to pass between the time the Claimant was readmitted and the attack on him. The Claimant has failed to prove any negligence on the part of the Department of Corrections. Furthermore, the Respondent is not responsible for acts of third parties under circumstances such as presented here. Mitchell v. State 1989 ; , 41 Ill. Ct. Cl. 124. ; Neither is the State an insurer as to the safety of an inmate in its custody. Petrusak v. State 1987 ; , 39 Ill. Ct. Cl. 113. ; Neither the Claimant or the State had any advance information which would have put the State on notice that the Claimant was likely to have been attacked. Therefore, the State is not guilty of negligence and the claim is denied.

Buy cheap baclofen

PP ROY, SK DAS, A SADHU Abstract Patients with bronchogenic carcinoma mainly present with chest related complaints. In advanced cases , the patient may present with metastasis viz. pathological fracture due to skeletal involvement, neurodeficit due to cerebral metastasis or at times paraneoplastic syndromes.A patient having bronchogenic carcinoma presented with problem of abnormal behaviour due to SIADH is reported here Ind J Radiol Imag 2006 16: 4: Key words : Bronchogenic Carcinoma , SIADH , abnormal behaviour Introduction : - Bronchogenic Carcinoma is the commonest cause of male death from primary malignant diseases 1 . Clinical manifestations vary from change in character of cough , haemoptysis , chest pain, breathlessness etc with or without features of metastasis in different tissues .Very rarely , lung cancer of small cell type may manifest with only features of SIADH Syndrome of inappropriate secretion of ADH ; without any evidence of SOL in lung in X-ray chest 2. Here is a patient who presented with abnormal behaviour due of SIADH a component of para-neoplastic syndrome ; as the only symptom, who was ultimately diagnosed as having lung cancer small cell carcinoma ; . Case Report : AA, a 52 years old male patient , admitted at Medical College , Kolkata on 6.6.2003 with marked breathlessness , fever and purulent expectoration for ten days . He was a known case of COPD and was on oral bronchodialator There was no history of haemoptysis or chest pain . Past history revealed nothing significant . He was a smoker who consumed one and a half pack of bidi per day for more than 20 years . On examination the following points were noted: - Anaemia - mild , Respiratory rate - 28 per min, Cyanosis absent . Accessory muscles of respiration- working . , AP diameter of thorax increased . Bilateral hyper-resonant note on percussion. Breath sound - Vescicular with prolonged expiration . Bilateral rhonchi present , crepitation present . CVS , CNS and GI system examition -No abnormality was detected. Investigations : - Haemoglobin - 13 gm % TLC - 12000 cu.mm. DLC-P72L20E8 , ESR - 20mm hr , PPBS 120mg% Urea - 22mg% , Creatinine -.7mg% . X-ray chest on 6.6.2003 showed evidence of emphysema . Fig 1 ; PFT could not be done .ECG - within normal limit . Ultrasonography of abdomen - NAD . Blood gas analysis - PaO2 -70mm , PaCO2 - 44 mm , PH -7.38 and zebeta.

The LaRue Medical Literacy Exercises were created by Charles LaRue through a grant from the Minnesota Department of Education under the supervision of the Minnesota Literacy Council. 2005 MN Dept of Education.

North Dakota law requires that an informed consent be signed by the person to be tested before an HIV test can be drawn NDCC 23-07.5-02 ; . North Dakota requires health care providers to report HIV positive patients to the North Dakota Department of Health NDCC 23-07-02.1 ; . Testing of some individuals is mandated by statute, including: Any individual convicted of a crime and imprisoned fifteen days or more NDCC 23-07-07.5 ; Any individual convicted of a sexual offense except cohabitation, indecent exposure, and bigamy ; NDCC 23-07-07.5 ; Any individual convicted on an offense involving the use of a controlled substance if the use involved any type of syringe or hypodermic needle NDCC 23-07-07.5 ; North Dakota permits that minors 14 years of age or older can consent to examination, care, or treatment of any sexually transmitted disease without parental consent. Interpretation of the statute is that it does apply to HIV antibody testing NDCC 14-1017.

Become a central part of your life perspective. Try to feel the messages of health coming from your inner-awareness and respond by adopting those things that improve and drop those things that degrade your health. With time you will develop a habit of unconscious healthful behavior that will fill you with a zest for life; an innerstrength from which your health will glow. 3. Opioid Drugs for Treatment of Chronic Intractable Pain.--An implantable infusion pump is covered when used to administer opioid drugs e.g., morphine ; intrathecally or epidurally for treatment of severe chronic intractable pain of malignant or nonmalignant origin in patients who have a life expectancy of at least 3 months and who have proven unresponsive to less invasive medical therapy as determined by the following criteria: o The patient's history must indicate that he she would not respond adequately to noninvasive methods of pain control, such as systemic opioids including attempts to eliminate physical and behavioral abnormalities which may cause an exaggerated reaction to pain and o A preliminary trial of intraspinal opioid drug administration must be undertaken with a temporary intrathecal epidural catheter to substantiate adequately acceptable pain relief and degree of side effects including effects on the activities of daily living ; and patient acceptance. 4. Coverage of Other Uses of Implanted Infusion Pumps.--Determinations may be made on coverage of other uses of implanted infusion pumps if the contractor's medical staff verifies that: o o and o The FDA approved labelling for the pump must specify that the drug being administered and the purpose for which it is administered is an indicated use for the pump. 5. Implantation of Infusion Pump Is Contraindicated.--The implantation of an infusion pump is contraindicated in the following patients: o Patients with a known allergy or hypersensitivity to the drug being used e.g., oral baclofen, morphine, etc. o o Patients who have an infection; Patients whose body size is insufficient to support the weight and bulk of the device; and The drug is reasonable and necessary for the treatment of the individual patient; It is medically necessary that the drug be administered by an implanted infusion pump!

Commercially obtained with a quality consistent with the european pharmacopeia ep ; , us pharmacopeia-national formulary, or internal specifications and lioresal. Approaching Death, supra, at 193 citations omitted ; . See also, Portenoy & Payne, supra, at 581; John P. Morgan, American Opiophobia: Customary Underutilization of Opioid Analgesics, in Controversies in Alcoholism and Substance Abuse 171 B. Stimmel, ed. 1986 Samuel Perry & George Heidrich, Management of Pain During Debridement: A survey of U.S. Burn Units, 13 Pain 267, 274 1982 Jane Porter and Hershel Hick, Correspondence, Addiction Rare in Patients Treated with Narcotics, 302 New Eng. J. of Med. 123 1980 ; . See also Stuart Davidson, Pain and Opiophobia, 40 Healthcare Forum J. 64, May June 1997 ; reporting that the evidence to support the "fear that dosages large enough to relieve pain will cause addiction" is merely anecdotal ; . 8.
More information can be obtained from: National Institute on Drug Abuse NIDA ; by logging on the NIDA website: drugabuse.gov or call toll free 1-888-644-6432.